Vanguard discloses 5.03% Vera Therapeutics (VERA) stake in Schedule 13G

Rhea-AI Filing Summary

The Vanguard Group reported beneficial ownership of 3,570,401 shares of Vera Therapeutics Inc. common stock, representing 5.03% of the outstanding class as of the event date. All shares are held with shared voting and dispositive power through Vanguard-managed client accounts.

Vanguard reports shared voting power over 489,258 shares and shared dispositive power over the full 3,570,401 shares, with no sole voting or dispositive authority. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Vera Therapeutics.

Insights

Institutional Ownership Analyst

Vanguard discloses a 5.03% passive stake in Vera Therapeutics.

The Vanguard Group reports beneficial ownership of 3,570,401 Vera Therapeutics shares, equal to 5.03% of the common stock. Voting and dispositive powers are reported as shared, reflecting holdings across Vanguard-managed client accounts rather than proprietary positions.

The certification explicitly states that the position was acquired and is held in the ordinary course of business and is not intended to change or influence control of Vera Therapeutics. That language aligns with a Schedule 13G passive ownership filing rather than an activist stance.

The narrative notes an internal realignment on January 12, 2026, after which certain Vanguard subsidiaries may report ownership on a disaggregated basis. Future Schedule 13D/G filings by related Vanguard entities could refine how this ownership is distributed across funds, but the disclosed 5.03% stake is the current consolidated figure.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Vera Therapeutics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

92337R101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 92337R101

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 489,258.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,570,401.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,570,401.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.03 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting. In accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Vera Therapeutics Inc
(b)	Address of issuer's principal executive offices: 170 Harbor Way, 3rd Floor, South San Francisco, CA, 94080
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 92337R101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3570401
(b)	Percent of class: 5.03 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 489258
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3570401
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	01/30/2026

FAQ

What percentage of Vera Therapeutics (VERA) shares does The Vanguard Group own?

The Vanguard Group reports beneficial ownership of 5.03% of Vera Therapeutics’ common stock. This represents 3,570,401 shares, held across Vanguard-managed client accounts, with Vanguard reporting shared voting and shared dispositive power rather than sole control over the position.

How many Vera Therapeutics (VERA) shares are beneficially owned by The Vanguard Group?

The Vanguard Group reports beneficial ownership of 3,570,401 Vera Therapeutics common shares. All of these shares are reported with shared dispositive power, and a subset of 489,258 shares carries shared voting power, with no sole voting or dispositive authority.

Is The Vanguard Group an activist investor in Vera Therapeutics (VERA) according to this filing?

No. Vanguard certifies the Vera Therapeutics shares were acquired and are held in the ordinary course of business. It states they were not acquired and are not held to change or influence control, consistent with a passive Schedule 13G filing.

What does shared voting and dispositive power mean for Vera Therapeutics (VERA) shares held by Vanguard?

Vanguard reports shared voting power over 489,258 shares and shared dispositive power over 3,570,401 shares. This indicates voting and selling decisions are exercised collectively for client accounts, with no sole authority over any Vera Therapeutics shares.

Who ultimately benefits from The Vanguard Group’s Vera Therapeutics (VERA) holdings?

The filing states that Vanguard’s clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds from the reported Vera Therapeutics shares. No single other person’s interest exceeds 5% of the class.

What internal changes at The Vanguard Group are mentioned in relation to the Vera Therapeutics (VERA) stake?

The document notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries or business divisions may report beneficial ownership separately. These units pursue the same investment strategies previously handled directly by The Vanguard Group.